


## *Ensuring patients safe access to the maximum extent possible*

We believe it is important to deliver new breakthrough therapies to patients who need them, and equally important to ensure patients safe access to the drugs' clinical benefits. To complement the approval of REVLIMID® in 2005, Celgene created the RevAssist<sup>SM</sup> program to provide for patient education and safety while ensuring relatively prompt and convenient access to REVLIMID. Under the RevAssist program, REVLIMID will be dispensed through a network of contracted pharmacies where trained nurses and pharmacists educate patients about potential risks before a prescription can be filled.

While RevAssist was specifically tailored for REVLIMID, it derives from our experience with our innovative System for Thalidomide Education and Prescribing Safety, or *S.T.E.P.S.*®, the first patented, FDA-approved risk-management drug distribution program.



Since its inception in 1998, *S.T.E.P.S.* has made it possible for more than 130,000 patients with various life-threatening and debilitating diseases to receive the potential therapeutic benefits of THALOMID. In turn, *S.T.E.P.S.* has become one of the most widely recognized, industry-leading programs for both patient safety and access. In late 2004, Celgene concluded non-exclusive licensing agreements with the manufacturers of isotretinoin. These companies now can make use of certain Celgene *S.T.E.P.S.* use-patents to develop risk-management programs that deliver this drug with important therapeutic benefits, but also has potentially serious side effects. Because

of the licensing agreements, patients can expect to take advantage of these risk-management distribution programs this year.

*S.T.E.P.S.*, and now RevAssist, reflect the Company's long-standing working partnership with government, advocacy groups and industry partners. They also reflect our commitment to both support patient access to innovative therapies and ensure that these therapies are prescribed appropriately.